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1 |  INTRODUCTION
A barrier to successful renal transplantation is the presence of 
ischemia/reperfusion (I/R) injury, affecting a third of trans-
plants (rising to a half when the donated organ is taken fol-
lowing circulatory arrest).1 This in turn results in significant 
disruption of allograft recovery through delayed graft func-
tion and episodes of acute rejection,2,3 which increases mor-
bidity and mortality (reviewed in 4). A key effector in I/R 
injury is the complement system, triggered by recognition 
molecules that detect ischemic changes and initiate an in-
flammatory response and downstream tissue damage.5
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Abstract
In a recent study, we identified a fucosylated damage-associated ligand exposed 
by ischemia on renal tubule epithelial cells, which after recognition by collectin-11 
(CL-11 or collectin kidney 1 (CL-K1)), initiates complement activation and acute 
kidney injury. We exploited the ability to increase the local tissue concentration of 
free l-fucose following systemic administration, in order to block ligand binding 
by local CL-11 and prevent complement activation. We achieved a thirty-five-fold 
increase in the intrarenal concentration of l-fucose following an IP bolus given  
before the ischemia induction procedure - a concentration found to significantly block 
in vitro binding of CL-11 on hypoxia-stressed renal tubule cells. At this l-fucose 
dose, complement activation and acute post-ischemic kidney injury are prevented, 
with additional protection achieved by a second bolus after the induction procedure.  
CL-11−/− mice gained no additional protection from l-fucose administration, indi-
cating that the mechanism of l-fucose therapy was largely CL-11-dependent. The 
hypothesis is that a high dose of l-fucose delivered to the kidney obstructs the carbo-
hydrate recognition site on CL-11 thereby reducing complement-mediated damage 
following ischemic insult. Further work will examine the utility in preventing post-
ischemic injury during renal transplantation, where acute kidney injury is known to 
correlate with poor graft survival.
K E Y W O R D S
collectin-11, complement, ischemia/reperfusion, l-fucose, lectin pathway, transplantation
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The complement system, an essential part of the innate 
immune system, is comprised of three activation pathways: 
classical, lectin and alternative.6 It acts through the central 
complement protein C3 and results in C3b deposition on cel-
lular surfaces. C3b is a marker for membrane attack complex 
(C5b-9) formation, which ultimately mediates cell damage.7 
It also drives an inflammatory response and aids in priming 
the adaptive immune system for the ultimate removal of an-
tigenic material.7,8 The classical and lectin pathways begin 
with pattern recognition molecules (PRMs) that recognize 
altered cell surface or foreign ligands. C1q is the principal 
PRM of the classical pathway,9 but there are several PRMs 
in the lectin pathway (reviewed in 10). The emphasis of our 
study is on Collectin-11 (CL-11), a lectin pathway PRM 
known to have significant expression throughout major or-
gans,11,12 and a major focus of recent work in our lab.13,14 
CL-11 is expressed in a number of organs15 and within the 
kidney it is predominantly expressed in the renal tubules 
but is also present in the glomerular mesangium and epithe-
lium.16 Structurally, CL-11 contains an N-terminal domain, a 
collagen-like region, a neck region, and a carbohydrate rec-
ognition domain (CRD),17 and is seen in the body as a hetero-
trimer with collectin-10 (CL-10). CL-10 has also been shown 
to be found in the kidney at the mRNA and protein level 
(15, reviewed in 18). Recombinant CL-11 binds with high 
affinity to sugar residues such as l-fucose and d-mannose but 
with lower affinity to d-galactose.11 Upon binding, CL-11, 
in complex with mannose binding lectin (MBL)-associated 
serine protease 2 (MASP-2), activates complement.5,19 Roles 
for CL-11 and complement have recently become clear in I/R 
injury and transplant models.13 3MC (Malpuech-Michels-
Mingarelli-Carnevale) syndrome is a rare human disease 
comprising a variety of developmental abnormalities, such 
as cleft lip and/or palate, facial dysmorphia, and craniosynos-
tosis, among other features.20 Research has shown that 3MC 
syndrome, although rare, can be caused by deficiency of var-
ious lectin pathway components, including CL-11, MASP-3 
and more recently CL-10.20,21
Work on mouse models of native and transplant kid-
ney I/R injury has shown a key role for the complement 
system. C3-deficient mice are protected from I/R injury, 
demonstrating the central role of C3.22 Further research 
in the same model has both ruled out classical pathway 
involvement and demonstrated a key role for MASP-2,5 
although it should be noted that MASP-2 can bypass 
C4 when complexed with MBL.23 Most recently, CL-11 
binding has been shown to increase following ischemic 
injury and is associated with the deposition of comple-
ment. This effect is initiated through interaction of CL-11 
with l-fucose, suggesting that the CRD on CL-11 recog-
nizes a fucosylated ligand on ischemic tissue.13 l-fucose 
is a deoxyhexose and a component of a number of glycans 
that have roles in various biological processes such as 
host-microbe interactions, blood transfusion reactions 
and a number of ontogenic events (24, reviewed in 25). In 
the kidney, it is detected by plant lectin mainly, if not ex-
clusively, on the proximal tubule. In a murine renal tu-
bule system, removal of fucose by fucosidase blocks the 
stress-induced deposition of CL-11 and, in turn, comple-
ment, as does pre-treatment of recombinant CL-11 with 
l-fucose.13 This has led to speculation that I/R injury in-
creases the number of sites to which CL-11 binds by alter-
ing either the presentation or the expression of fucosylated 
ligand on renal tubular epithelial cell surfaces. It is en-
visaged that exposed fucosyl residues are recognized and 
bound by CL-11. Once CL-11 binds to these residues it 
acts to activate complement, in turn resulting in C3 depo-
sition, generation of an inflammatory response and kidney 
damage. The hypothesis underlying this study is that el-
evating the level of l-fucose in the kidneys prior to, and 
during I/R injury would prevent CL-11 binding and con-
sequently reduce post-ischemic injury in a way that could 
be clinically beneficial. This study uses a well-established 
mouse I/R injury to investigate this hypothesis.5,13,22
2 |  METHODS
2.1 | Yeast invertase/collectin-11  
enzyme-linked immunosorbent assay (ELISA)
MediSorp microtiter plates (Thermo Fisher, Loughborough, 
UK) were coated overnight at 4°C with 2 µg/mL invertase 
from Candida utilis (Sigma,  Gillingham, Dorset, UK) in 
0.05 M carbonate-bicarbonate (Sigma, Gillingham, Dorset, 
UK). Plates were blocked for 2 hours at room temperature 
(RT) with tris buffered saline (TBS)/Tw/Ca + 0.1% bovine 
serum albumin (BSA). The rCL-11 (3 µg/mL)26 and mono-
saccharide inhibitor (l-fucose [Sigma, Gillingham, Dorset, 
UK], d-mannose [Sigma Gillingham, Dorset, UK], or d-
galactose [Sigma, Gillingham, Dorset, UK]), diluent alone, 
or 10 mM ethylenediaminetetraacetic acid (EDTA) solution 
were mixed in 1:1 ratio prior to incubation overnight at 4°C. 
Further details of the rCL-11 used throughout this paper are 
summarised in supplementary Figure 1, which shows it run 
on a reducing and a non-reducing gel alongside a gel filtra-
tion analysis. It should also be noted that this rCL-11 is not 
biotinylated. Plates were incubated with rabbit anti-human 
CL-11 at 1:1000 (Abcam, Cambridge, UK) for 1 hour at RT 
followed by goat anti-rabbit-horseradish peroxidase (HRP) 
at 1:3000 (Cell Signalling Technologies, London, UK) for 
1 hour at RT. The plate was developed with 1-Step Ultra 
TMB-ELISA (Thermo Fisher, Loughborough, UK) and opti-
cal density (OD) measured at 450 nm. Concentrations of the 
buffer components used are as follows: 10 mM Tris, 145 mM 
NaCl, 0.05% Tween-20, 2 mM CaCl2, pH 7.4.
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2.2 | Animals
CL-11−/− mice were purchased from Mutant Mouse 
Resource and Research Centres (MMRRC) (UC Davis, CA, 
USA)27 and backcrossed to C57BL/6 background for four 
generations. Male mice at 8 weeks of age were used in all 
experiments with wildtype (WT) offspring of these crosses 
used as controls.13 All experiments adhered to the Animals 
(Scientific Procedures) Act 1986.
2.3 | Proximal tubule epithelial cell cultures
Primary Proximal Tubule Epithelial Cell (PTEC) cul-
tures from CL-11−/− kidneys were prepared as described 
previously.28 Briefly, the cortex was excised from mouse 
kidney, and digested with 0.1% (w/v) collagenase type II 
(Worthington Biochemical Corporation, Lakewood, NJ, 
USA) in Dulbecco’s modified eagle medium (DMEM)/
F12 and passed through a series of sieves, culminating with 
a 40-μm nylon sieve. Cells were cultured on cover slips in 
24 well plates preincubated for 2 hours with 1% (w/v) gela-
tine. Cells were cultured for 5-7 days in DMEM/F12 medium 
containing 2% Fetal Calf serum (FCS), 1% Pen/Strep (P/S), 
insulin (5 μg/mL), transferrin (5 μg/mL), selenium (5 ng/mL), 
hydrocortisone (40 ng/mL), and triiodothyronine (10–12M).
2.4 | Induction of PTEC stress
PTECs were transferred to a hypoxia chamber (Billups-
Rothenberg, CA, USA) and purged with 5% CO2, 1% O2 and 
F I G U R E  1  Fucose distribution over time following intraperitoneal (IP) injection. A, Confirmation of K-fucose kit (megazyme) specificity, 
showing detection of increasing concentrations of l-fucose, d-mannose and d-galactose compared with manufacturer’s l-fucose standard.  
B, l-fucose measurements in serum and kidney following a single IP injection of 100 mg of l-fucose, at 5, 10, 20, 25 and 30 min and then 15-min 
intervals to 60 minutes and 120 and 240 min. C, l-fucose measurements in serum and kidney samples following a second IP injection of 100 mg  
l-fucose (given 60 min after the first dose) at the listed time points following the second dose, up to 60 min. Kidneys were homogenized and 
l-fucose concentration was determined in homogenized lysate and serum. Kidney values are adjusted to weight of kidney. Each data point is 
representative of at least two biological repeats and three technical repeats. Error bars on all graphs are standard error of the mean 
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94% N2 at 20 L/min for 5 minutes, then incubated at 37°C 
overnight. Cells were allowed to recover at normoxia  at 
37°C for 2 hours. They were then incubated with 10% serum 
from either  WT or  CL-11–/– mice, or phosphate buffered 
serum (PBS) as a control. All serums and PBS was diluted in 
culture medium (without FCS), and the cells were placed at 
37°C for 1 hour. Human rCL-11 (0.9 µg/mL)26 was added to 
CL-11-/- mouse serum 30 minutes prior to addition to PTECs 
alongside l-fucose, d-galactose or culture media (without 
FCS). Cells were washed, fixed in 4% (w/v) paraformalde-
hyde (PFA) in PBS for 10 minutes, and immunohistochem-
istry performed.
2.5 | Injection of l-fucose
Mice received intraperitoneal (250 µL; IP) injection of 
400 mg/mL l-fucose or d-galactose in PBS. Post-ischemic 
doses were injected into the abdominal cavity before suturing.
2.6 | Induction of renal I/R Injury
Injury was induced as previously described.13 Mice were 
anesthetized using isofluorane (Abbott, Maidenhead, UK) 
and placed on a heating pad. Following laparotomy, renal 
artery and vein were isolated and occluded using microaneu-
rysm clamps (Codman, UK). Once the clamps were removed, 
0.5 mL warm saline, l-fucose or d-galactose solution 
(400 mg/mL) was placed in the abdomen, the incision was 
sutured, and the animals were allowed to recover in a warm 
box. Mice were culled 24 hours later. Kidneys and blood 
were taken for analysis.
2.7 | Assessment of renal function
Serum was collected from whole blood. A standard kit (BUN 
Infinity) was used to assess Blood Urea Nitrogen (BUN). All 
measurements were normalized to the mean WT BUN for a 
given experiment. Experiments were combined and analyzed 
as a whole dataset.
2.8 | Assessment of renal histopathology
Kidneys were fixed in 4% (w/v) PFA in PBS overnight 
at 4°C then embedded in paraffin. Sections (4-7 μm) 
were stained with periodic acid-Schiff reagent (PAS). 
Corticomedullary junction tubular injury was graded using 
a 5-point scale: 0, normal kidney; 1, <10% necrosis; 2, 
10%–25%; 3, 25%–75%; and 4, >75%, in a blinded fashion 
by two experimenters.29
2.9 | Immunohistochemistry
Kidneys were fixed in Phosphate-Lysine-Periodate (PLP) for 
2 hours at 4°C and incubated in 13% (w/v) sucrose overnight 
at 4°C. Kidneys were coronally dissected and embedded in 
optimal cutting temperature (OCT) compound (CellPath, 
Newtown, Powys, UK). Frozen sections (4 μm) were air dried 
overnight at RT, washed and blocked with 20% (v/v) goat or 
donkey serum in PBS. Sections were incubated with poly-
clonal rabbit anti-human C3d (1:200; A0063, Dako, Agilent, 
Santa Clara, CA, USA), rat anti-mouse Ly-6B.2 mAb (1:100; 
MCA771G, Serotec, Kidlington, UK); rat anti-mouse CD45 
Ab (clone 30-F11; 1:100; MCD4500, Caltag, Buckingham, 
UK); or rat anti-F4/80 Ab (clone CL:A3-1; 1:100; MCA497, 
Bio-rad, Hertfordshire, UK) followed by FITC-conjugated 
goat anti-rabbit IgG Ab (1:100; 111-095-144, Stratech 
Scientific, Cambridge, UK), goat anti-rat Alexa Fluor 488 
(1;200; a11006, Invitrogen, Thermo Fischer, Loughborough, 
UK) or donkey anti-rabbit Alexa Fluor 594 (1:200; 406418, 
Life Technologies, Thermo Fischer, Loughborough, UK) at 
RT for an hour. Antibodies were diluted in 20% blocking 
buffer and nuclei stained with 4′,6-diamidino-2-phenylindole 
(DAPI) (1:10  000; Life Technologies, Thermo Fischer, 
Loughborough, UK).
2.10 | l-Fucose analysis
Serum was prepared as described above. Whole kidney 
was homogenized in 1M perchloric acid. Homogenate was 
adjusted to pH 8.0, volume adjusted to equalize samples and 
incubated on ice. Next, 1 mL of homogenate was spun for 
10 minutes and the supernatant applied to a K-fucose kit 
(Megazyme, Wicklow, Ireland). Samples were added to a 
solution containing nicotinamide adenine dinucleotide phos-
phate  (NADP+) in a 96 well plate and preincubated at 37°C 
for 3 minutes. l-fucose dehydrogenase was then added and 
the plate was incubated for 15 minutes at 37°C. The product 
of this reaction was then measured by absorbance at 340 nm 
and l-fucose concentrations calculated from a standard curve 
made using known l-fucose quantities. Serum was adjusted to 
mg/mL and kidney fucose was normalized to kidney weight 
([mg/mL]/g).
2.11 | Imaging infiltrating cells and 
C3d expression
Tissue staining was visualized using microscopy and quanti-
fied using ImageJ (NIH). Infiltrating leukocytes within the 
corticomedullary junction were counted at a magnification 
of 20×, and the percentage of C3d deposition per image was 
calculated by setting a threshold for background removal. 
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From a minimum of three fields per animal, the number of 
immune cells/C3d deposition was determined.
2.12 | Statistics
Data are shown as the mean ± SEM or as values for indi-
vidual data points. For comparisons between two groups, an 
unpaired, 2-tailed Student’s t test was used, and a P value of 
less than .05 was considered significant. For three or more 
groups, pairwise comparisons of specific groups were under-
taken and again a P value of less than .05 was considered sig-
nificant. All statistics were performed using GraphPad Prism, 
version 8 (GraphPad Software).
3 |  RESULTS
3.1 | Levels of administered l-fucose rapidly 
rise and fall in serum but remain stable in the 
kidney over several hours
We applied increasing concentrations of l-fucose alongside 
two alternative sugars to a commercial fucose kit to demon-
strate its specificity (Figure 1A). We then took readings of 
serum and kidney l-fucose levels at intervals following IP 
injection (Figure 1B). l-fucose rapidly distributes to both the 
serum and the kidney and then  in the case of serum levels 
return to pre-IP injection levels at 2 hours. However, in the 
kidney  l-fucose levels remain at a low, but above baseline 
level past 4 hours. At early time-points the variability of the 
serum L-fucose measurements was considerable, especially 
between 5 and 20 minutes. Biological repeats were more 
consistent at subsequent time-points. The initial inter-mouse 
variability could have been due to technical differences, such 
as variations in pressure of injection and exit from the perito-
neal cavity into the blood, which evened out over time with 
homeostatic control.
Serum l-fucose levels peaked at 10 minutes at 9.1 (±4.2) 
mg/mL before rapidly decreasing to 4.5 (±0.01) mg/mL at 
30 minutes and 2.5 (±0.29) mg/mL at 60 minutes. The kid-
ney concentration took longer to reach its maximal l-fucose 
concentration of 8.35 (±0.26) (mg/mL)/g at 25 minutes. But 
the kidney sustained these levels, with the intrarenal l-fucose 
concentration being 8.30 (±0.59) (mg/mL)/g at 30 minutes 
and 4.15 (±0.31) (mg/mL)/g after 60 minutes. Thus, the kid-
ney concentration of l-fucose following 400 mg/mL IP ad-
ministration was maintained at a level of at least 46 times 
(peaking at over 95 times) the normal kidney concentration 
(0.090 [±0.016] [mg/mL]/g) for over 1 hour and remained at 
10 times the basal level after 4 hours, when the serum con-
centration had returned to normal (0.070 [±0.010] mg/mL). 
A second injection 60 minutes after the first maintained the 
raised concentration of l-fucose in the kidney for a longer 
period, while similarly transient kinetics occurred in the 
serum (Figure 1C). The peak after the second injection is 
not only substantially higher (12.2 [±1.1] [mg/mL]/g) than 
that of the single injection, but the duration of supraphysi-
ologic fucose levels is extended beyond 120 minutes, where 
the l-fucose remains at 6.04 (±0.14) (mg/mL)/g. It should 
be noted that the peak intrarenal level of l-fucose (between 
2 and 2.6 mg/mL) occurs between 15 and 30 minutes (and 
between 70 and 105 minutes after a second dose); a work-
ing concentration between 12 and 16 mM. Additionally, after 
two l-fucose injections, the mouse kidney remained at a level 
above 8 mM until 120 minutes post-first injection.
3.2 | l-fucose blocks CL-11 binding to a 
similar extent as d-mannose but a greater 
extent than d-galactose on immobilised 
yeast invertase
To establish a functional concentration of l-fucose needed 
to block CL-11 binding, we performed in vitro sugar block-
ing studies. Utilizing a previously published ELISA method26 
of CL-11 binding to a known ligand, we added a number of 
sugars to establish the extent of CL-11 blockade (l-fucose, 
d-Mannose and d-galactose) up to the level of a no Ca2+(EDTA) 
control (Figure 2). The half maximal inhibitory concentration 
(IC50) for l-fucose and d-galactose was 12.12 mM and 11.75 mM 
respectively, while d-galactose was approximately half as 
effective (IC50 of 20). This agrees with known affinities of 
CL-11 for different sugars11 and shows that d-galactose is 
a suitable control molecule for all other experiments in this 
study. The IC50 of l-fucose in our ELISA (12.12 mM) approxi-
mates the level measured in the kidney following IP injection 
(and indeed for the double IP injection). Importantly, as clamp-
ing the renal blood vessels at 60 minutes after the IP injec-
tion is assumed to block the exit of fucose from the kidney, 
the levels of l-fucose are likely to remain between 8 mM and 
16 mM during the first hour of reperfusion.
3.3 | In a cell culture system, l-fucose blocks 
rCL-11-induced deposition of complement
PTECs isolated from CL-11−/− mice were exposed to hypoxic 
stress. The subsequent addition of WT serum (ie, containing 
CL-11) to the culture led to cell-surface deposition of C3d, 
consistent with complement activation, while CL-11−/− serum 
does not, as previously shown.13 Adding 0.9 µg/mL of rCL-11 
to CL-11−/− serum, ensured the presence of rCL-11 alongside 
other complement factors, and this resulted in C3d deposition. 
It should be noted that we use human rCL-11 on these cells 
as we have previously found this to be effective in activating 
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complement.13 It has been shown in the literature that human 
and mouse CL-11 have the same preference for l-fucose 
over other sugar residues,11,12 and consequently we are con-
fident that these findings using human rCL-11 are applicable 
to the role of CL-11 in the mouse kidney. To this was added 
l-fucose or d-galactose control in various amounts to give a 
final concentration of 0.06 mg/mL (0.37 mM), 1.3 mg/mL (8 
mM) and 13 mg/mL (80 mM), where 0.06 mg/mL (0.37 mM) 
corresponds to the normal serum level, 1.3 mg/mL (8 mM) to 
the measured level sustained in the kidney for 60 minutes fol-
lowing two IP injections (Figure 1) and 13 mg/mL (80 mM) 
to 10 times this amount. The presence of l-fucose in normal 
serum levels did not reduce C3d deposition, but at supra-
physiologic levels of l-fucose (1.3 mg/mL), C3d deposition 
was reduced by approximately 60%, compared to d-galactose 
-treated or no-added-sugar controls (Figure 3). A similar level 
of complement inhibition occurred with the highest dose of 
l-fucose (13 mg/mL), suggesting that a local tissue concentra-
tion of 1.3 mg/mL would be a reasonable therapeutic target to 
block CL-11-associated complement deposition.
3.4 | Supraphysiologic levels of renal l-
fucose demonstrate a protective effect against 
I/R injury
To investigate the potential therapeutic application of l-fucose 
in renal I/R injury we used an established murine model. This 
model is characterized by an increased expression of fuco-
sylated molecules alongside CL-11 bound to the basolateral 
surface of the proximal renal tubules at 24 hours of reperfusion 
following 30 minute ischemia.13 Furthermore, the model elicits 
a role for local complement in the pathogenesis of the ischemic 
injury29 and a role for CL-11.13 We tested two regimens of 
l-fucose administration. First, mice received a single IP bolus 
of l-fucose 60 minutes prior to induction of ischemia. The re-
sulting concentration of l-fucose during the 30 minutes of is-
chemia was 0.62 (±0.014) mg/mL (or 4.15 (±0.31) (mg/mL)/g 
normalized to kidney weight) or a working concentration of 
3.84 mM, which gradually fell after reperfusion (Figure 1B). 
Under these conditions, there was a significant reduction in 
F I G U R E  2  Monosaccharide Inhibition of CL-11 binding. A, Level of CL-11 binding to immobilized yeast invertase measured using enzyme-
linked immunosorbent assay (ELISA). l-fucose, d-mannose and d-galactose were added at increasing values to determine blocking of CL-11. 
Values are blank-corrected OD450 measurements. Dotted line is the average of all blank-corrected EDTA-treated wells which corresponds to a 
functionally zero value for CL-11 binding (which is known to be calcium-dependent). B, Sugar inhibition of CL-11 binding to yeast invertase. 
Lower dotted line represents 100% inhibition, middle dotted line represents 50% inhibition, and higher dotted line represents no inhibition.  
C, Table of half maximal inhibitory concentration (IC50) values calculated form data presented in (A) and (B). Each data point is representative of 
at least two biological repeats and three technical repeats. Error bars on all graphs are standard error of the mean. IC50 was calculated using a four-
parameter logistic curve, while graphs show a best fit line 
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the mean kidney injury compared with d-galactose-injected 
controls, despite notable inter-mouse variation (mean BUNs 
of 33.68 mmol/L and 20.21 mmol/L for d-galactose and 
l-fucose, respectively; Figure 4A). In the second regimen, 
mice received two successive IP doses of l-fucose, 60 min-
utes prior to I/R injury as before, and a second dose imme-
diately following reperfusion. As a result, the renal l-fucose 
concentration was at least 10 mM by 10 minutes after reperfu-
sion and remained above 11 mM from 20 minutes, therefore 
achieving levels above those of the previous experiment over a 
longer period. Analysis of kidney function (Figure 4B) (mean 
BUNs of 30.98 mmol/L and 19.68 mmol/L for d-galactose and 
l-fucose respectively) and tubule necrosis (Figure 4C,D) 
showed a reduction of acute kidney injury in l-fucose -treated 
mice. A decrease in complement (C3d) deposition (Figure 4E,F) 
in l-fucose -treated mice showed a parallel reduction in com-
plement activation on the vulnerable segments of renal tubules, 
as previously described.13,22,29
3.5 | Pre-treatment with l-fucose reduces 
immune cell infiltration associated with 
complement system activation
To further corroborate the effect of l-fucose pre-treatment 
on complement-mediated inflammation, we analyzed the tis-
sue infiltrate of immune cells. Using markers for neutrophils 
(Ly-6B.2), leukocytes (CD45) and macrophages (F4/80) we 
showed a significant reduction in the number of immune cells 
infiltrating into the corticomedullary junction (Figure 5). 
F I G U R E  3  Quantification of C3d deposition on hypoxia-stressed mouse PTECs. CL-11−/− mouse PTECs were stressed by 16 hours of 
hypoxia and this was followed by addition of 10% normal mouse serum (NMS) or CL-11−/− serum. To CL-11−/− serum was added 0.9 µg/mL 
rCL-11 and different levels of l-fucose or d-galactose, or no sugar. A, Percentage of C3d-positive staining determined from 12 individual fields 
and representative of three independent experiments. B, and C, representative images of cells used for quantification in (A). Each data point is 
representative of at least three biological repeats and three technical repeats. Error bars on all graphs are standard error of the mean. ***P < .005 
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F I G U R E  4   l-Fucose has a protective effect on mouse kidneys after IR injury induction. Individual mice were dosed intraperitoneally with 
100 mg of l-fucose or d-galactose 1 h before induction of 30 min bilateral renal ischemia (A) or both 1 hour before clamping and immediately after 
removal of clamps (B). Renal function (BUN) was measured in serum 24 hours post-reperfusion and normalized within each individual experiment 
before being combined. Mean BUNs were (A) 33.68 mmol/L and 20.21 mmol/L, and (B) 30.98 mmol/L and 19.68 mmol/L for d-galactose and  
l-fucose, respectively. C and D, representative images of PAS staining of mouse kidneys from (B) (n = 6 mice/group), at 10x (C) or 20x (D) 
magnification. E and F, representative images of C3d staining (red) of mouse kidneys from (B) (n = 7 mice/group), at 10× (E) or 20× (F) 
magnification. G, Quantification of C3d staining shown in E. Scale bars = 100 µm. Error bars on all graphs are standard error of the mean.  
*P < .05, **P < .01, ***P < .005 
D-g
ala
cto
se
L-f
uc
os
e
0.0
0.5
1.0
1.5
R
el
at
iv
e 
to
 W
T 
B
U
N
D-g
ala
cto
se
L-f
uc
os
e
0
1
2
3
4
Se
ve
rit
y 
Sc
or
e
(A) (B)
(H)
(G)(C)
(D)
(E)
(F)
ΎΎΎΎ
Ύ
ΎΎ
D-g
ala
cto
se
L-f
uc
os
e
0.0
0.5
1.0
1.5
R
el
at
iv
e 
to
 W
T 
B
U
N
D-g
ala
cto
se
L-f
uc
os
e
0
2
4
6
8
10
C
3d
-p
os
iti
ve
 a
re
a 
(%
)
830 |   HOWARD et Al.
Thus, in addition to blocking activation of the complement, 
l-fucose blockade of CL-11 also reduces the recruitment of 
immune and inflammatory cells.
3.6 | The protective  
effect of l-fucose is dependent on  
CL-11 and the complement system
According to our hypothesis, fucose treatment acts by ob-
structing CL-11 binding to target ligand on ischemic renal 
tissue, and therefore the administration of l-fucose should 
be ineffective when CL-11 is absent. In contrast, if fucose 
acted through a CL-11-independent mechanism, an additive 
effect would be evident. The treatment of CL-11-deficient 
mice with l-fucose afforded no additional protection 
against the development of renal I/R injury, compared with 
d-galactose -treated mice (Figure 6), including loss of renal 
function (mean BUNs were 45.77 mmol/L, 13.98 mmol/L and 
13.56 mmol/L for WT d-galactose, CL-11−/− d-galactose and 
CL-11−/− l-fucose respectively [Figure 6A]), renal comple-
ment (C3d) deposition (Figure 6B) and leukocyte infiltration 
F I G U R E  5  Impact of l-fucose on immune cell infiltration after 30 min of ischemia. Individual mice were dosed intraperitoneally with 
100 mg of l-fucose or d-galactose 1 h before induction of 30 min bilateral renal ischemia and again at the time the clamps were removed. Renal 
function (BUN) was measured in serum 24 h post-reperfusion. A, Representative images of immunochemical staining of neutrophils in kidneys 
sections from mice with l-fucose or d-galactose IP injections. B, Quantification of neutrophils in kidney sections from the mice represented in 
A. C, Representative images of immunochemical staining of leukocytes in kidney sections from mice with l-fucose or d-galactose IP injections. 
D, Quantification of leukocytes in kidney sections from the mice represented in C. E, Representative images of immunochemical staining of 
macrophages in kidneys sections from mice with l-fucose or d-galactose IP injections. F, Quantification of macrophages in kidney sections from 
the mice represented in E. Scale bars = 100 µm. All images are representative of staining (n = 7 and n = 5 mice/group for d-galactose and l-fucose 
groups respectively). Error bars on all graphs are standard error of the mean. ***P < .005 
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F I G U R E  6  Absence of CL-11 renders l-fucose therapy ineffective in renal I/R injury. Individual mice were dosed intraperitoneally with 
100 mg of l-fucose or d-galactose 1 h before induction of 30 min bilateral renal ischemia and again at the time the clamps were removed. Renal 
function (BUN) was measured in serum 24 h post-reperfusion (A). Mean BUNs were 45.77 mmol/L, 13.98 mmol/L and 13.56 mmol/L for WT with 
d-galactose, CL-11−/− with d-galactose and CL-11−/− with l-fucose, respectively. B, Representative images of fluorescent C3 staining of mice in A. 
F, Quantification of C3d staining in B. C, Representative images of immunochemical staining of neutrophils in kidneys sections from the mice in 
A. G, Quantification of neutrophils in kidney sections from the mice represented in A and C. D, Representative images of immunochemical staining 
of leukocytes in kidneys sections from the mice in A. H, Quantification of leukocytes in kidney sections from the mice represented in A and D. 
E, Representative images of immunochemical staining of macrophages in kidneys sections from the mice in A. I, Quantification of macrophages 
in kidney sections from the mice represented in A and E. Scale bars = 100 µm. All images are representative of staining (n = 6 for CL-11+/+ 
d-galactose, n = 4 for CL-11−/− d-galactose, and n = 5 for CL-11−/− l-fucose). Error bars on all graphs are standard error of the mean. *P < .05, 
***P < .005
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(Figure 6C–E). Not only does this suggest that the effect of 
l-fucose treatment was CL-11-dependent, but it also indicates 
that there is no major independent effect of the treatment on 
glycan-receptor interactions that mediate leukocyte migration 
(reviewed in 30). These findings are consistent with a pharma-
cological effect of l-fucose primarily on a CL-11-mediated 
pathway of post-ischemic renal injury in our model.
4 |  DISCUSSION
Our study provides a rational basis for considering l-fucose 
a potential therapeutic approach to the inhibition of renal I/R 
injury. Previous work has shown that CL-11 plays a key role 
in the initiation of complement-mediated damage to renal 
tubules following I/R injury and this is likely due to the 
binding of CL-11 to a fucosylated ligand. In vitro analysis 
previously showed that free l-fucose inhibited the binding 
of recombinant CL-11 to a proposed damage-associated li-
gand.13 Therefore, would saturating the kidney with an ex-
cess of free l-fucose, prior to I/R injury, block CL-11 binding 
to its damage-associated ligand and likewise diminish com-
plement-mediated injury? Our data establishes that an excess 
of free fucose in the kidney following systemic administra-
tion is sustainable for a critical period and protects against 
development of hypoxia-induced acute kidney injury.
Throughout this discussion we use both the words inhibit 
and block. We specifically use block as we refer to the physical 
obstruction of the CRD on CL-11 by l-fucose but this should 
not be understood to mean a complete blockade of all CL-11 
functions in these circumstances. The extent of the block var-
ies depending on levels of l-fucose as the discussed below.
The concentration of soluble l-fucose in the renal cortex 
following a double IP bolus injection (Figure 1) is sufficient 
for in vitro blockade of CL-11 binding on immobilized ligand 
(Figure 2) and inhibition of complement activation on hy-
poxic renal tubule cells (Figure 3). When l-fucose was added 
at a normal serum level (0.06 mg/mL), complement depo-
sition was not blocked; however when added at 1.3 mg/mL 
(8mM), corresponding to the kidney concentration at 60 min-
utes following double IP injection (Figure 1), complement 
deposition was mostly prevented (Figure 3A). Higher l-fu-
cose concentrations did not substantially increase the block-
ing effect. In contrast, a monosaccharide such as d-galactose 
with only weak binding to the CRD on CL-11 had no major 
inhibitory effect.
In our ELISA blocking assay (Figure 2) we use a rCL-11  
that has been used both in our lab13 and several others.26,31 
It is a recombinant homo-oligomer generated by expression 
of the CL-11 cDNA (isoform a). It consists primarily of 
monomers and dimers (and smaller amounts of larger oligo-
mers) of a subunit composed of three polypeptide chains 
(Supplementary Figure 1). Previous studies have shown that 
it binds to MASPs with high affinities,31 similar to those of 
MBL-MASP and ficolin-MASP complexes.32,33 Moreover, 
rCL-11 activates complement with comparable activity to 
recombinant human MBL (~2.5-fold lower), in human serum 
depleted of endogenous lectins.26 This ELISA establishes 
l-fucose blocks rCL-11 (Figure 2) at a concentration that 
approximates the amount of fucose present in the kidney at 
the induction of I/R injury. Mannose blocks rCL-11 bind-
ing to a similar extent as l-fucose (IC50 of 11.75 and 12.12, 
respectively), approximating that previously published.26 
Meanwhile d-galactose is about half as effective, justifying 
the use of d-galactose as a control throughout this study. It 
has been reported that d-mannose and l-fucose blocking of 
CL-11 binding are as effective as each other, while d-galactose 
is considerably less effective in blocking CL-11 binding to 
mannose-BSA.11
Thus, in vitro, l-fucose blocks the binding of CL-11 to im-
mobilized ligand and inhibits CL-11-mediated complement 
deposition on cultured cells, consistent with the protective ef-
fect of systemic administration of l-fucose we found in vivo. 
These data support the proposed therapeutic mechanism in 
which the local tissue concentration of l-fucose is elevated to 
a level that competitively blocks CL-11 binding to ischemic 
tissue, eliminating the trigger for complement activation. There 
is a possibility that the mode of l-fucose action is through a 
different pathway than via CL-11 signalling and consequently 
we looked at its effect in CL-11−/− mice. We observed no ad-
ditional protective effect in CL-11-deficient mice treated with 
l-fucose; specifically complement activation and leukocyte in-
filtration were no less in the l-fucose -treated CL-11-deficient 
mice than in d-galactose-treated controls (Figure 6). The data 
are consistent with a decoy mechanism whereby the raised 
concentration of free l-fucose in the renal interstitium blocks 
CL-11 binding to fucosylated ligand and so prevents trigger-
ing of complement activation by the lectin pathway. We did 
consider using fucosyltransferase (FUT)-deficient mice as a 
means to test the impact of fucosylation on ischaemic injury; 
however, the wide range of molecules and biological functions 
likely to be affected by deficient fucosylation even with a spe-
cific FUT deletion would be unlikely to localize the effect of 
ligand disruption to collectin-11. Rather, the findings in CL-11 
deficient mice treated with l-fucose are against a major effect 
of the sugar on leukocyte-receptor-ligand interaction mediating 
leukocyte migration and are in keeping with a primary mode 
of action of l-fucose blocking the carbohydrate recognition 
domain of CL-11. Further work to make this definitive will 
require increased knowledge of the kidney glycome as well as 
details of the specific ligand for CL-11 in this process.
In achieving sustainable local tissue concentrations of 
l-fucose following IP administration, we noted important dif-
ferences between the two regimens using single (Figure 4A) 
and repeated (Figure 4B) doses. Longer exposure time to 
   | 833HOWARD et Al.
maintain an effective inhibitory concentration occurred 
with repeated dosing of l-fucose compared to a single dose. 
The data indicate that with a single IP injection of l-fucose, 
CL-11 binding is significantly but not consistently blocked 
(Figure 4A) (P = .0351). If it is assumed that l-fucose lev-
els remain broadly constant during ischemia, since both 
renal artery and vein are occluded, then upon the removal 
of renal clamps and the commencement of reperfusion, the 
second dose causes a substantial increase in kidney l-fucose 
as well as a prolonged exposure to this higher concentration, 
which returns gradually to steady state over the next 24 hours 
(data not shown). This increased kidney l-fucose causes a 
more significant reduction in kidney damage as well as a 
reduction of inter-mouse variation (Figure 4B) (P =  .001). 
The finding of normal tissue concentration of l-fucose in 
d-galactose-treated mice confirmed that the elevation in l- 
fucose was related to l-fucose injection, rather than ischemic 
damage per se.
The results presented here have obvious clinical impli-
cations for the prevention of I/R injury and delayed graft 
function.34 Delayed renal graft function is a common man-
ifestation of acute post-ischemic kidney injury, especially 
in diseased-donor organ transplantation, and has adverse 
effects on graft immunogenicity and long-term graft sur-
vival.35 The potential value for therapy is enhanced by lack 
of toxicity observed in our mice and in previously reported 
animal and human studies. l-fucose is a natural constituent 
of many glycans that are presented at the cell membrane 
of mammalian cells.25 Previous cancer studies have shown 
that IP injections of l-fucose are not detrimental in mice up 
to a level of 5 g/kg (approximately 160 mg).36 Additionally, 
low-molecular-weight fucoidan (LMWF), a group of 
fucose-enriched sulphated polysaccharides extracted from 
seaweed, was shown to have a protective effect on I/R injury 
in mice,37 though the mechanism was not fully explained. 
The circulating levels of l-fucose following IP adminis-
tration in our studies were between 40 and 130 times the 
normal level in mice, and these equate to the levels in 
human subjects treated with l-fucose in previous studies.38 
One hour following oral fucose administration levels were 
between 20× and 40× normal serum levels with a max-
imum of 75× (for leukocyte adhesion deficiency II 
(LAD II)38,39), approximating our findings detailed here. In 
particular, no change in animal behavior or feeding habit 
was evident in our mice.
Further optimization of the fucose-delivery protocol may 
be possible, depending on the application being considered. 
For example, a constant infusion protocol could lead to 
steady-state tissue-fucose concentration for a longer period 
and possibly reduce inter-subject variation and increase the 
degree of protection. Pre-emptive treatment of donated kid-
neys that are intended for use in organ transplantation may 
also be feasible.
Our results validate the general concept that fucosylated 
structures mediate the binding of CL-11 to hypoxic renal 
tubule cells and that soluble l-fucose is a competitive in-
hibitor that binds to the carbohydrate recognition domain of 
CL-11. The results showing a therapeutic effect of supra-
physiological levels of l-fucose within the renal cortex, com-
bined with the in vitro effect on the cell binding properties of 
CL-11, make a strong case for further investigation. This is 
particularly relevant in renal transplant ischemia reperfusion 
injury, where the risk of delayed graft function is ever pres-
ent given the more frequent use of marginal donors.
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